Use of gemtuzumab ozogamycin combined with conventional chemotherapy in patients with acute myeloid leukemia

被引：0

作者：

Perini, Guilherme Fleury ^{[1
]}

de Souza Santos, Fabio Pires ^{[1
]}

Esteves, Iracema ^{[1
]}

Bley do Nascimento, Claudia Mac-Donald ^{[1
]}

Rodrigues, Morgani ^{[1
]}

de Assis, Reijane Alves ^{[1
]}

Helman, Ricardo ^{[1
]}

Kutner, Jose Mauro ^{[1
,2
]}

Feitosa Ribeiro, Andreza Alice ^{[1
,2
]}

Hamerschlak, Nelson ^{[1
,3
]}

机构：

[1] Hosp Israelita Albert Einstein HIAE, Hematol & Bone Marrow Transplantat, Sao Paulo, Brazil

[2] Hosp Israelita Albert Einstein HIAE, Hemotherapy, Sao Paulo, Brazil

[3] Medula Ossea Hosp Israelita Albert Einstein, Hematol Programa Transplante Medula, Avenida Albert Einstein 627-701,Predio A1, Sao Paulo, Brazil

来源：

EINSTEIN-SAO PAULO | 2011年 / 9卷 / 02期

关键词：

Leukemia; myeloid; acute/drug therapy; Radiotherapy; Antineoplastic agents/therapeutic use; Antineoplastic combined chemotherapy protocols/therapeutic use; Aged;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective: To analyze the outcome of patients treated with gemtuzumab ozogamycin combined with conventional therapy treated at Hospital Israelita Albert Einstein. Methods: 14 patients who had high risk features (secondary leukemia, unfavorable cytogenetics, and refractory disease) were treated with gemtuzumab ozogamycin combined with conventional therapy and their outcome was analysed by reviewing their medical records. Results: Overall response rate was 58%, with 43% achieving complete response, with a median followup of 11 months, event-free survival was 3 months. Eleven patients died, 6 of them due to refractory acute myeloid leukemia. Only four patients presented with grade 3 to 4 toxicities and only one patient had sinusoidal obstruction syndrome after bone marrow transplant. Conclusion: gemtuzumab ozogamycin combined with chemotherapy is a feasible treatment regimen in acute myeloid leukemia patients. However, further studies are necessary to clarify which subgroup of patients may benefit from this treatment.

引用

页码：190 / 195

页数：6

共 26 条

[1] Gemtuzumab ozogamicin (Mylotarg®) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia:: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups [J].

Amadori, S ;

Suciu, S ;

Stasi, R ;

Willemze, R ;

Mandelli, F ;

Selleslag, D ;

Denzlinger, C ;

Muus, P ;

Stauder, R ;

Berneman, Z ;

Pruijt, J ;

Nobile, F ;

Cassibba, V ;

Marie, JP ;

Beeldens, F ;

Baila, L ;

Vignetti, M ;

de Witte, T .

LEUKEMIA, 2005, 19 (10) :1768-1773

[2] Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19) [J].

Amadori, Sergio ;

Suciu, Stefan ;

Selleslag, Dominik ;

Stasi, Roberto ;

Alimena, Giuliana ;

Baila, Liliana ;

Rizzoli, Vittorio ;

Borlenghi, Erika ;

Gaidano, Gianluca ;

Magro, Domenico ;

Torelli, Giuseppe ;

Muus, Petra ;

Venditti, Adriano ;

Cacciola, Emma ;

Lauria, Francesco ;

Vignetti, Marco ;

de Witte, Theo .

BRITISH JOURNAL OF HAEMATOLOGY, 2010, 149 (03) :376-382

[3]

Bloomfield CD, 1998, CANCER RES, V58, P4173

[4] Sustained molecular remission after low dose gemtuzumab-ozogamicin in elderly patients with advanced acute promyelocytic leukemia [J].

Breccia, Massimo ;

Cimino, Giuseppe ;

Diverio, Daniela ;

Gentilini, Fabiana ;

Mandelli, Franco ;

Lo Coco, Francesco .

HAEMATOLOGICA, 2007, 92 (09) :1273-1274

[5]

Bross PF, 2001, CLIN CANCER RES, V7, P1490

[6] Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial [J].

Burnett, Alan K. ;

Hills, Robert K. ;

Milligan, Donald ;

Kjeldsen, Lars ;

Kell, Jonathan ;

Russell, Nigel H. ;

Yin, John A. L. ;

Hunter, Ann ;

Goldstone, Anthony H. ;

Wheatley, Keith .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04) :369-377

[7] REPORT OF THE NATIONAL CANCER INSTITUTE-SPONSORED WORKSHOP ON DEFINITIONS OF DIAGNOSIS AND RESPONSE IN ACUTE MYELOID-LEUKEMIA [J].

CHESON, BD ;

CASSILETH, PA ;

HEAD, DR ;

SCHIFFER, CA ;

BENNETT, JM ;

BLOOMFIELD, CD ;

BRUNNING, R ;

GALE, RP ;

GREVER, MR ;

KEATING, MJ ;

SAWITSKY, A ;

STASS, S ;

WEINSTEIN, H ;

WOODS, WG .

JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (05) :813-819

[8] Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia [J].

Cheson, BD ;

Bennett, JM ;

Kopecky, KJ ;

Büchner, T ;

Willman, CL ;

Estey, EH ;

Schiffer, CA ;

Döhner, H ;

Tallman, MS ;

Lister, TA ;

LoCocco, F ;

Willemze, R ;

Biondi, A ;

Hiddemann, W ;

Larson, RA ;

Löwenberg, B ;

Sanz, MA ;

Head, DR ;

Ohno, R ;

Bloomfield, CD .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (24) :4642-4649

[9] Long-Term Disease-Free Survival After Gemtuzumab, Intermediate-Dose Cytarabine, and Mitoxantrone in Patients With CD33+ Primary Resistant or Relapsed Acute Myeloid Leukemia [J].

Chevallier, Patrice ;

Delaunay, Jacques ;

Turlure, Pascal ;

Pigneux, Arnaud ;

Hunault, Mathilde ;

Garand, Richard ;

Guillaume, Thierry ;

Avet-Loiseau, Herve ;

Dmytruk, Nathalia ;

Girault, Stephane ;

Milpied, Noel ;

Ifrah, Norbert ;

Mohty, Mohamad ;

Harousseau, Jean-Luc .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (32) :5192-5197

[10] Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease [J].

Cohen, AD ;

Luger, SM ;

Sickles, C ;

Mangan, PA ;

Porter, DL ;

Schuster, SJ ;

Tsai, DE ;

Nasta, S ;

Gewirtz, AM ;

Stadtmauer, EA .

BONE MARROW TRANSPLANTATION, 2002, 30 (01) :23-28

← 1 2 3 →